Teva Settles 16-Year Cipro Pay-For-Delay Litigation For $225M; Will Focus Shift To Pricing Deals?
California indirect purchasers reached previous settlements with Bayer and three other firms; plaintiffs’ attorney sees shift from reverse-payment to price fixing and market swapping cases. Trump appointments to FTC could influence direction of scrutiny.
You may also be interested in...
In addition to settling with Endo, FTC refiles charges against Watson (now Teva), Allergan and Impax involving Lidoderm and Opana ER patent litigation settlements.
Heritage Pharmaceuticals’ former CEO and former president charged by US DOJ with conspiracy to fix prices and allocate customers for doxycycline and glyburide; Heritage alleges they embezzled intellectual property.
$1.2 billion agreement resolving Provigil litigation with FTC blocks Teva from entering business deal with competitor until 30 days after patent settlement that restricts generic entry, sets $7 million cap on litigation savings.